BALTIMORE--(BUSINESS WIRE)--Cerecor Inc., a clinical-stage biopharmaceutical company developing proprietary treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that Blake Paterson, MD, CEO and Co-Founder, will present a corporate overview at the 13th Annual BIO Investor Forum in San Francisco, CA, taking place October 7-8, 2014. The presentation on October 8, 2014, at 10am PT will highlight Cerecor’s lead product candidate, CERC-301, which is in Phase 2 development as a potential first-in-class, oral, adjunctive therapy for patients with major depressive disorder (MDD). CERC-301 has the potential to rapidly reduce depressive symptoms, including suicidality, in severely depressed patients through the selective antagonism of the NMDA receptor subunit 2B (NR2B).
Cerecor Inc (“Cerecor”) is a Baltimore-based biopharmaceutical company developing proprietary treatments to make a difference in the lives of patients with neurological and psychiatric diseases by addressing the unmet medical needs of underserved patient segments. We are committed to the development of drugs that improve lives by applying our extensive knowledge and experience in central nervous system disorders. www.cerecor.com